Behçet's disease uveitis.
Agents anti-TNFα
Anti-TNFα agents
Behçet's disease
Biotherapies
Biothérapies
Maladie de Behçet
Uveitis
Uvéite
Vascularite
Vasculitis
Journal
La Revue de medecine interne
ISSN: 1768-3122
Titre abrégé: Rev Med Interne
Pays: France
ID NLM: 8101383
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
09
05
2023
accepted:
06
06
2023
pubmed:
7
7
2023
medline:
7
7
2023
entrez:
6
7
2023
Statut:
ppublish
Résumé
Uveitis in Behçet's disease (BD) is frequent (40% of cases) and is a major cause of morbidity. The age of onset of uveitis is between 20 and 30 years. Ocular involvement includes anterior, posterior or panuveitis. It is non-granulomatous. Uveitis may be the first sign of the disease in 20% of cases or it may appear 2 or 3 years after the first symptoms. Panuveitis is the most common presentation and is more commonly found in men. Bilateralisation usually occurs on average 2 years after the first symptoms. The estimated risk of blindness at 5 years is 10-15%. BD uveitis has several ophthalmological features that distinguish it from other uveitis. The main goals in the management of patients are the rapid resolution of intraocular inflammation, prevention of recurrent attacks, achievement of complete remission, and preservation of vision. Biologic therapies have changed the management of intraocular inflammation. The aim of this review is to provide an update previous article by our team on pathogenesis, diagnostic approaches, identification of factors associated with relapse and the therapeutic strategy of BD uveitis.
Identifiants
pubmed: 37414674
pii: S0248-8663(23)00667-7
doi: 10.1016/j.revmed.2023.06.004
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
546-554Informations de copyright
Copyright © 2023 Société Nationale Française de Médecine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.